HYDERABAD, India I February 9, 2017 I Aurobindo Pharma Limited is pleased to announce the acquisition of four cell culture derived biosimilar products from TL Biopharmaceutical AG. As part of this agreement, TL will supply all the developmental data for four molecules and Aurobindo and/or its affiliates will develop, commercialize and market these products globally. The branded market size of these four biosimilars, three of them monoclonal antibodies in oncology is very promising. Regulatory filing for these products is intended in the period 2020-22.
Aurobindo is preparing to take its lead molecule from this transaction, a Bevacizumab biosimilar, for clinical trials in 2017. Bevacizumab is an anti-antiogenesis drug used in treating multiple-cancers including metastatic colon or rectal cancer, non-squamous and non-small cell lung cancers.
This transaction is a strategic investment for future growth and will position Aurobindo as a strong player in the rapidly evolving biosimilars landscape. Building on these first four products licensed from TL, Aurobindo is expanding its diverse portfolio of eight more next wave of biosimilars ensuring a strong and diverse products pipeline. Aurobindo has set up a fully functional R&D center for biologics development and is also establishing a state-of-art manufacturing facility in Hyderabad, Telangana which would be ready by Q2, FY 18
Commenting on the strategic alliance, Mr. N. Govindarajan, Managing Director of Aurobindo Pharma Limited said: We are impressed with TL’s product development as these are developed to the highest standards of biosimilarity. This acquisition is in-line with our strategy of investing in complex products and is an important step towards establishing Aurobindo’s global biosimilars portfolio. About Aurobindo Pharma Limited:
Aurobindo Pharma Limited (www.aurobindo.com) (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP:IN), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company’s robust product portfolio is spread over seven major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, Anti-Allergies and Anti-Diabetics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 150 countries.
SOURCE: Aurobindo Pharma
Post Views: 15
HYDERABAD, India I February 9, 2017 I Aurobindo Pharma Limited is pleased to announce the acquisition of four cell culture derived biosimilar products from TL Biopharmaceutical AG. As part of this agreement, TL will supply all the developmental data for four molecules and Aurobindo and/or its affiliates will develop, commercialize and market these products globally. The branded market size of these four biosimilars, three of them monoclonal antibodies in oncology is very promising. Regulatory filing for these products is intended in the period 2020-22.
Aurobindo is preparing to take its lead molecule from this transaction, a Bevacizumab biosimilar, for clinical trials in 2017. Bevacizumab is an anti-antiogenesis drug used in treating multiple-cancers including metastatic colon or rectal cancer, non-squamous and non-small cell lung cancers.
This transaction is a strategic investment for future growth and will position Aurobindo as a strong player in the rapidly evolving biosimilars landscape. Building on these first four products licensed from TL, Aurobindo is expanding its diverse portfolio of eight more next wave of biosimilars ensuring a strong and diverse products pipeline. Aurobindo has set up a fully functional R&D center for biologics development and is also establishing a state-of-art manufacturing facility in Hyderabad, Telangana which would be ready by Q2, FY 18
Commenting on the strategic alliance, Mr. N. Govindarajan, Managing Director of Aurobindo Pharma Limited said: We are impressed with TL’s product development as these are developed to the highest standards of biosimilarity. This acquisition is in-line with our strategy of investing in complex products and is an important step towards establishing Aurobindo’s global biosimilars portfolio. About Aurobindo Pharma Limited:
Aurobindo Pharma Limited (www.aurobindo.com) (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP:IN), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company’s robust product portfolio is spread over seven major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, Anti-Allergies and Anti-Diabetics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 150 countries.
SOURCE: Aurobindo Pharma
Post Views: 15
